GGrantIndex
← Leaderboards

Christopher Williams

Tulane University Of Louisiana

$5,047,884
Attributed
$8,047,884
Total exposure
4
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $6.8M · FY200725
$10M$7.5M$5M$2.5M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$21,120,502 · 5

By mechanism

U54$13,072,618 · 1
S21$6,000,000 · 1
SC1$1,136,000 · 1
K01$483,832 · 1
SC3$428,052 · 1

Top collaborators

Most similar at Tulane University Of Louisiana

Same institution · by research overlap

Others in their field

Top investigators on “Signal Transduction

Research focus

Signal TransductionMediatingMalignant NeoplasmsMalignant Breast NeoplasmMutationSelective Estrogen Receptor ModulatorsTamoxifenSkillsEstrogen AntagonistsResistanceFacultyPhosphotransferasesCasein Kinase IiReceptor SignalingLigandsEstrogen ReceptorsPhosphorylationCareerIn VivoTumorLeadBreast Cancer CellMammary NeoplasmsAntineoplastic Agents

Grant awards (21)

The RCMI Center for Cancer and Health Disparities Research$4,656,808
U54 · FY2025 · MD
PREDICT (Precision Medicine, Education, Data Informatics and Community Translation) Institute$2,000,000
S21 · FY2025 · MD
Evaluating DR2 agonism as a potential therapeutic approach to substance abuse and traumatic brain injury$75,000
U54 · FY2025 · MD
RCMI Center for Cancer and Health Disparities Research$4,798,100
U54 · FY2024 · MD
PREDICT (Precision Medicine, Education, Data Informatics and Community Translation) Institute$2,000,000
S21 · FY2024 · MD
RCMI Center for Cancer and Health Disparities Research$3,331,400
U54 · FY2023 · MD
PREDICT (Precision Medicine, Education, Data Informatics and Community Translation) Institute$2,000,000
S21 · FY2023 · MD
Effect of CX4945 in tamoxifen resistant BCa$284,000
SC1 · FY2023 · GM · contact PI
Developing a First in Class Reverse Transcriptase Degrader for the Treatment of HIV Infection$211,310
U54 · FY2023 · MD
Effect of CX4945 in tamoxifen resistant BCa$284,000
SC1 · FY2022 · GM · contact PI
Effect of CX4945 in tamoxifen resistant BCa$284,000
SC1 · FY2021 · GM · contact PI
Effect of CX4945 in tamoxifen resistant BCa$284,000
SC1 · FY2020 · GM · contact PI
Induction of a tumor-hostile breast cancer microenvironment by metformin$108,240
SC3 · FY2018 · GM · contact PI
Induction of a tumor-hostile breast cancer microenvironment by metformin$107,470
SC3 · FY2017 · GM · contact PI
Induction of a tumor-hostile breast cancer microenvironment by metformin$106,723
SC3 · FY2016 · GM · contact PI
Induction of a tumor-hostile breast cancer microenvironment by metformin$105,619
SC3 · FY2015 · GM · contact PI
Novel Estrogen Receptor Phosphorylation Sites in Sensitivity/Resistance to SERMs$100,627
K01 · FY2011 · CA · contact PI
Novel Estrogen Receptor Phosphorylation Sites in Sensitivity/Resistance to SERMs$98,640
K01 · FY2010 · CA · contact PI
Novel Estrogen Receptor Phosphorylation Sites in Sensitivity/Resistance to SERMs$96,710
K01 · FY2009 · CA · contact PI
Novel Estrogen Receptor Phosphorylation Sites in Sensitivity/Resistance to SERMs$94,837
K01 · FY2008 · CA · contact PI
Novel Estrogen Receptor Phosphorylation Sites in Sensitivity/Resistance to SERMs$93,018
K01 · FY2007 · CA · contact PI